Amid a chaotic biopharma ecosystem and declining revenues, Charles River Laboratories is initiating a strategic review and shaking up its board. The CRO’s board will “conduct a comprehensive strategic review and evaluation of Charles River’s business and prospects,” the company said in a May 7 release, “including an examination of various alternatives to enhance long-term stockholder value.” In addition, Charles River’s board has appointed four new directors, with four currently serving board members deciding not to seek re-election, according to the release.
Read the full article: Charles River Launches Strategic Review and Shakes up Board amid Regulatory Uncertainty, Sliding Revenue //
Source: https://www.fiercebiotech.com/cro/charles-river-launches-strategic-review-and-shakes-board-amid-regulatory-uncertainty-sliding